Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY2127399 in rheumatoid arthritis patients with inadequate response to TNFα inhibitors
2008-001105-42Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing LY2127399 + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR50 response at 24 weeks. Started Jul 2008; status: completed.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-001105-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001105-42.